8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 12, 2026·SEC
Capricor Therapeutics, Inc.(CAPR)Earnings, Financials & Key Ratios
CAPR•NASDAQ
Price updated Jun 17, 2026
AboutCapricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.Show more
- Revenue$0-100.0%
- EBITDA-$108M-162.9%
- Net Income-$105M-159.6%
- EPS (Diluted)-2.26-96.5%
- ROE-46.56%+3.3%
CAPR Key Insights
Capricor Therapeutics, Inc. (CAPR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 88 (top 12%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 50.4% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 32.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CAPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CAPR Price & Volume
Capricor Therapeutics, Inc. (CAPR) stock price & volume — 10-year historical chart
Loading chart...
CAPR Growth Metrics
Capricor Therapeutics, Inc. (CAPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-108.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-63.38%
Return on Capital
10 Years-85.9%
5 Years-67.49%
3 Years-61.13%
Last Year-46.06%
CAPR Recent Earnings
Capricor Therapeutics, Inc. (CAPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (57%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.59-7.3%
$0.55
Rev
—
$40M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.62-21.6%
$0.51
Rev
—
$525,000
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.54+0.0%
$0.54
Rev
—
$600,000
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.57-18.8%
$0.48
Rev
—
$480,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.59vs $0.55-7.3% | —vs $40M |
| Q2 2026 | Mar 12, 2026 | $0.62vs $0.51-21.6% | —vs $525,000 |
| Q4 2025 | Nov 10, 2025 | $0.54vs $0.54+0.0% | —vs $600,000 |
| Q3 2025 | Aug 11, 2025 | $0.57vs $0.48-18.8% | —vs $480,000 |
Based on last 12 quarters of dataView full earnings history →
CAPR Peer Comparison
Capricor Therapeutics, Inc. (CAPR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.79B | 16.96 | -2.38 | 15.58% | 2.98% | 4.89% | 0.91 | |
 CRSP | 5.12B | 53.09 | -8.21 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EXEL | 13.32B | 52.44 | 18.86 | 6.98% | 35.08% | 40.21% | 0.08 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.65B | 26.91 | -4.62 | 20.13% | -91.03% | -6.08% | ||
 EDIT | 249.66M | 2.55 | -1.42 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.71B | 15.20 | -3.99 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.34B | 32.48 | -40.10 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare CAPR vs Peers
Capricor Therapeutics, Inc. (CAPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CAPR Income Statement
Capricor Therapeutics, Inc. (CAPR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.67M | 1.67M | 1.01M | 310.25K | 244.9K | 2.55M | 25.18M | 22.27M | 0 | 0 |
Revenue Growth % | -16.43% | -37.32% | -39.85% | -69.13% | -21.06% | 941.85% | 886.81% | -11.55% | -100% | -100% |
Cost of Goods Sold | 0 | 0 | 5.14M | 0 | 0 | 21.82M | 36.45M | 49.97M | 0 | 42.41M |
COGS % of Revenue | - | - | 511.61% | - | - | 855.07% | 144.76% | 224.37% | - | - |
Gross Profit | 2.67M▲ 0% | 1.67M▼ 37.3% | -4.14M▼ 347.6% | 310.25K▲ 107.5% | 244.9K▼ 21.1% | -19.27M▼ 7966.7% | -11.27M▲ 41.5% | -27.7M▼ 145.8% | 0▲ 100.0% | -42.41M▲ 0% |
Gross Margin % | 100% | 100% | -411.61% | 100% | 100% | -755.07% | -44.76% | -124.37% | - | - |
Gross Profit Growth % | 122.14% | -37.32% | -347.56% | 107.5% | -21.06% | -7966.74% | 41.5% | -145.77% | 100% | - |
Operating Expenses | 4.76M | 17M | 3.6M | 14M | 21.18M | 10.43M | 12.81M | 14.87M | 108.14M | 77.53M |
OpEx % of Revenue | 178.66% | 1017.24% | 357.91% | 4512.56% | 8649.86% | 408.86% | 50.87% | 66.76% | - | - |
Selling, General & Admin | 4.76M | 4.93M | 3.6M | 5.54M | 7.61M | 10.43M | 12.81M | 14.87M | 23.69M | 27.02M |
SG&A % of Revenue | 178.66% | 295.15% | 357.91% | 1786.69% | 3108.35% | 408.86% | 50.87% | 66.76% | - | - |
Research & Development | 10.77M | 12.07M | 5.14M | 8.46M | 13.57M | 21.82M | 36.45M | 49.97M | 84.45M | 92.92M |
R&D % of Revenue | 403.83% | 722.14% | 511.61% | 2725.87% | 5541.51% | 855.07% | 144.76% | 224.37% | - | - |
Other Operating Expenses | -10.77M | 0 | -5.14M | 0 | 0 | -21.82M | -36.45M | -49.97M | 0 | -2M |
Operating Income | -12.86M▲ 0% | -15.33M▼ 19.2% | -7.73M▲ 49.5% | -13.69M▼ 77.0% | -20.94M▼ 52.9% | -29.7M▼ 41.8% | -24.08M▲ 18.9% | -42.56M▼ 76.8% | -108.14M▼ 154.1% | -119.93M▲ 0% |
Operating Margin % | -482.45% | -917.24% | -769.52% | -4412.56% | -8549.86% | -1163.93% | -95.63% | -191.13% | - | - |
Operating Income Growth % | 24.24% | -19.16% | 49.54% | -77.01% | -52.95% | -41.83% | 18.92% | -76.78% | -154.06% | - |
EBITDA | -12.72M | -15.17M | -7.56M | -13.55M | -20.69M | -29.16M | -23.01M | -41.14M | -108.14M | -118.95M |
EBITDA Margin % | -477.04% | -907.8% | -752.41% | -4366.18% | -8449.54% | -1143.04% | -91.39% | -184.73% | - | - |
EBITDA Growth % | 24.53% | -19.28% | 50.15% | -79.14% | -52.76% | -40.94% | 21.11% | -78.8% | -162.87% | -113.24% |
D&A (Non-Cash Add-back) | 144.17K | 157.65K | 171.96K | 143.89K | 245.7K | 533.13K | 1.07M | 1.43M | 0 | 981K |
EBIT | 2.83M | -15.33M | -7.73M | -13.69M | -20.94M | -29.7M | -24.08M | -42.56M | -108.14M | -118.22M |
Net Interest Income | -398.81K | 0 | 0 | 0 | 0 | 521.53K | 1.73M | 2.2M | 3.21M | 5.39M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 521.53K | 1.73M | 2.2M | 6.26M | 8.43M |
Interest Expense | 398.81K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.05M | 3.05M |
Other Income/Expense | 15.29M | 135.99K | 92.07K | 32.94K | 915.92K | 677.85K | 1.79M | 2.1M | 3.1M | 5.34M |
Pretax Income | 2.43M▲ 0% | -15.19M▼ 724.9% | -7.64M▲ 49.7% | -13.66M▼ 78.7% | -20.02M▼ 46.6% | -29.02M▼ 44.9% | -22.29M▲ 23.2% | -40.47M▼ 81.6% | -105.04M▼ 159.6% | -114.59M▲ 0% |
Pretax Margin % | 91.19% | -909.1% | -760.36% | -4401.94% | -8175.86% | -1137.37% | -88.52% | -181.71% | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | 2.43M▲ 0% | -15.19M▼ 724.9% | -7.64M▲ 49.7% | -13.66M▼ 78.7% | -20.02M▼ 46.6% | -29.02M▼ 44.9% | -22.29M▲ 23.2% | -40.47M▼ 81.6% | -105.04M▼ 159.6% | -114.59M▲ 0% |
Net Margin % | 91.19% | -909.1% | -760.36% | -4401.94% | -8175.86% | -1137.37% | -88.52% | -181.71% | - | - |
Net Income Growth % | 112.93% | -724.89% | 49.7% | -78.71% | -46.61% | -44.93% | 23.2% | -81.57% | -159.58% | -108.11% |
Net Income (Continuing) | 2.43M | -15.19M | -7.64M | -13.66M | -20.02M | -29.02M | -22.29M | -40.47M | -105.04M | -114.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.90▲ 0% | -5.17▼ 674.4% | -2.06▲ 60.2% | -0.88▲ 57.3% | -0.87▲ 1.1% | -1.18▼ 35.6% | -0.83▲ 29.7% | -1.15▼ 38.6% | -2.26▼ 96.5% | -2.00▲ 0% |
EPS Growth % | 108.88% | -674.44% | 60.15% | 57.28% | 1.14% | -35.63% | 29.66% | -38.55% | -96.52% | -63.38% |
EPS (Basic) | 1.00 | -5.17 | -2.06 | -0.88 | -0.87 | -1.18 | -0.83 | -1.15 | -2.26 | - |
Diluted Shares Outstanding | 2.68M | 2.94M | 3.71M | 15.57M | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M | 57.43M |
Basic Shares Outstanding | 2.32M | 2.94M | 3.71M | 15.57M | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M | 57.43M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CAPR Balance Sheet
Capricor Therapeutics, Inc. (CAPR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.71M | 8.47M | 10.54M | 33.68M | 36.44M | 42.89M | 50.86M | 163.39M | 322.94M | 283.09M |
Cash & Short-Term Investments | 14.12M | 7.26M | 9.89M | 32.67M | 34.89M | 41.42M | 39.49M | 151.52M | 318.13M | 278.61M |
Cash Only | 6.14M | 4.26M | 3.9M | 32.67M | 34.89M | 9.6M | 14.69M | 11.29M | 287.85M | 105.42M |
Short-Term Investments | 7.98M | 3M | 5.99M | 0 | 0 | 31.82M | 24.79M | 140.23M | 30.28M | 173.19M |
Accounts Receivable | 344.57K | 204.87K | 87.97K | 56K | 391.75K | 547.58K | 10.37M | 10.37M | 59.17K | 0 |
Days Sales Outstanding | 47.18 | 44.75 | 31.95 | 65.88 | 583.87 | 78.33 | 150.36 | 169.93 | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 742K | 285.83K | 0 | -56K | 0 | 919.89K | 0 | 0 | 0 | 4.48M |
Total Non-Current Assets | 561.11K | 775.77K | 568.91K | 941.71K | 4.89M | 7.21M | 7.88M | 7.1M | 33.01M | 43.19M |
Property, Plant & Equipment | 372.1K | 574.21K | 442.81K | 850.85K | 4.62M | 6.94M | 7.61M | 6.87M | 18.31M | 41.66M |
Fixed Asset Turnover | 7.16x | 2.91x | 2.27x | 0.36x | 0.05x | 0.37x | 3.31x | 3.24x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 93.05K | 204.87K | 6.5K | 2.17K | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 95.97K | 151.79K | 119.61K | 88.7K | 275.72K | 268.17K | 268.17K | 221.7K | 14.7M | 1.53M |
Total Assets | 16.27M▲ 0% | 9.25M▼ 43.2% | 11.11M▲ 20.2% | 34.62M▲ 211.5% | 41.33M▲ 19.4% | 50.09M▲ 21.2% | 58.73M▲ 17.2% | 170.48M▲ 190.3% | 355.95M▲ 108.8% | 326.28M▲ 0% |
Asset Turnover | 0.16x | 0.18x | 0.09x | 0.01x | 0.01x | 0.05x | 0.43x | 0.13x | - | 0.00x |
Asset Growth % | -13.19% | -43.18% | 20.19% | 211.5% | 19.39% | 21.21% | 17.25% | 190.26% | 108.79% | 505.96% |
Total Current Liabilities | 1.67M | 1.26M | 897.99K | 2.97M | 4.13M | 23.59M | 31.27M | 21.03M | 35.84M | 33.64M |
Accounts Payable | 1.67M | 1.26M | 897.99K | 2.72M | 0 | 4.83M | 6.24M | 8.18M | 1.65M | 3.93M |
Days Payables Outstanding | - | - | 63.75 | - | - | 80.88 | 62.49 | 59.76 | - | 28.22 |
Short-Term Debt | 0 | 0 | 0 | 246.69K | 0 | 0 | 0 | 0 | 6.42M | 7.18M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 17.98M | 0 | 0 | 12M | 48M |
Other Current Liabilities | 0 | 0 | 0 | 0 | 3.72M | 0 | 24.27M | 12M | 0 | 6.73M |
Current Ratio | 9.40x | 6.75x | 11.74x | 11.33x | 8.82x | 1.82x | 1.63x | 7.77x | 9.01x | 8.42x |
Quick Ratio | 9.40x | 6.75x | 11.74x | 11.33x | 8.82x | 1.82x | 1.63x | 7.77x | 9.01x | 8.42x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 3.38M | 3.38M | 3.38M | 3.45M | 5.83M | 14.72M | 4.86M | 3.99M | 14.32M | 13.94M |
Long-Term Debt | 0 | 0 | 0 | 71.47K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 2.45M | 1.88M | 1.49M | 616.32K | 14.32M | 42.88M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 3.38M | 0 | 0 |
Total Liabilities | 5.05M | 4.63M | 4.27M | 6.42M | 9.96M | 38.31M | 36.13M | 25.02M | 50.16M | 47.58M |
Total Debt | 0 | 0 | 0 | 318.16K | 2.87M | 2.56M | 2.24M | 1.45M | 20.94M | 21.12M |
Net Debt | -6.14M | -4.26M | -3.9M | -32.35M | -32.01M | -7.04M | -12.46M | -9.84M | -266.9M | -84.3M |
Debt / Equity | - | - | - | 0.01x | 0.09x | 0.22x | 0.10x | 0.01x | 0.07x | 0.08x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.18x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.71x |
Interest Coverage | 7.10x | - | - | - | - | - | - | - | -35.51x | -38.82x |
Total Equity | 11.23M▲ 0% | 4.62M▼ 58.9% | 6.84M▲ 48.2% | 28.2M▲ 312.3% | 31.37M▲ 11.2% | 11.79M▼ 62.4% | 22.6M▲ 91.8% | 145.46M▲ 543.6% | 305.79M▲ 110.2% | 278.7M▲ 0% |
Equity Growth % | 380.45% | -58.89% | 48.18% | 312.31% | 11.23% | -62.43% | 91.76% | 543.6% | 110.22% | 1064.08% |
Book Value per Share | 4.19 | 1.57 | 1.84 | 1.81 | 1.36 | 0.48 | 0.84 | 4.13 | 6.58 | 4.85 |
Total Shareholders' Equity | 11.23M | 4.62M | 6.84M | 28.2M | 31.37M | 11.79M | 22.6M | 145.46M | 305.79M | 278.7M |
Common Stock | 26.27K | 3.14K | 5.23K | 20.58K | 24.18K | 25.24K | 31.15K | 45.58K | 57.37K | 57.66K |
Retained Earnings | -51.55M | -66.74M | -74.38M | -88.04M | -108.06M | -137.08M | -159.37M | -199.83M | -304.88M | -338.82M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 11.62K | 12.39K | -757 | 0 | 0 | 105.24K | 235.81K | 1.03M | 283.15K | -253.73K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CAPR Cash Flow Statement
Capricor Therapeutics, Inc. (CAPR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.23M | -13.86M | -6.82M | -10.05M | -16.81M | 4.92M | -25.6M | -40M | -69.81B | -92.63M |
Operating CF Margin % | -533.79% | -829.59% | -678.74% | -3240.87% | -6863.81% | 192.7% | -101.66% | -179.59% | - | - |
Operating CF Growth % | 9.94% | 2.59% | 50.79% | -47.4% | -67.18% | 129.25% | -620.61% | -56.25% | -174446.73% | -546.86% |
Net Income | 2.43M | -15.19M | -7.64M | -13.66M | -20.02M | -29.02M | -22.29M | -40.47M | -105.04B | -114.59M |
Depreciation & Amortization | 144.17K | 157.65K | 171.96K | 143.89K | 245.7K | 533.13K | 1.07M | 1.43M | 1.89B | 1.25B |
Stock-Based Compensation | 1.71M | 1.73M | 700.98K | 1.95M | 2.97M | 4.46M | 7.39M | 9.77M | 16.97B | 3.98B |
Deferred Taxes | 0 | 0 | 0 | -325.89K | -310.25K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -15.65M | 2.32M | 2.72K | 325.89K | 129.73K | 196.01K | -18.24K | 65.54K | 16.36B | 75.39B |
Working Capital Changes | -2.86M | -554.59K | -55.34K | 1.51M | 182.34K | 28.75M | -11.75M | -10.78M | 12.2M | -1.52M |
Change in Receivables | -121.24M | 139.71M | 116.9M | 87.97M | -391.75M | -155.83K | -9.82M | 3.5K | 10.31M | 59.83K |
Change in Inventory | 121.36M | -139.79M | 156.28M | -1.91B | 391.75M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.86M | -415.46K | -273.18M | 1.83B | 991.17K | 1.21M | 1.33M | 1.94M | 5.98M | 1.59M |
Cash from Investing | 4.98M | 4.67M | -3M | 5.44M | -1.2M | -35.07M | 5.11M | -116.18M | 97.48B | -81.05M |
Capital Expenditures | -32.19K | -316.49K | 0 | -547.6K | -1.2M | -3.36M | -2.05M | -1.54M | -2.9B | -2.02B |
CapEx % of Revenue | 1.21% | 18.94% | - | 176.5% | 488.48% | 131.68% | 8.13% | 6.91% | - | - |
Acquisitions | 0 | 0 | 0 | -5.99M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 5.01M | 4.99M | 0 | 5.99M | 0 | 0 | 0 | 0 | -8.82B | -82.12B |
Cash from Financing | 11.58M | 6.85M | 9.18M | 33.38M | 20.23M | 4.87M | 25.58M | 152.77M | 248.89B | 250.31M |
Debt Issued (Net) | 500K | 0 | 0 | 318.16K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 11.07M | 6.71M | 9.17M | 27.34M | 20.17M | 4.8M | 25.52M | 152.32M | 248.89M | 250.31M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -193 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 6.64K | 139.14K | 3.22K | 5.72M | 50.56K | 70.3K | 64.6K | 450.17K | 248.64B | 0 |
Net Change in Cash | 2.33M▲ 0% | -2.34M▼ 200.3% | -645.77K▲ 72.4% | 28.77M▲ 4554.6% | 2.22M▼ 92.3% | -25.28M▼ 1239.1% | 5.09M▲ 120.1% | -3.41M▼ 166.9% | 276.56B▲ 8115463.7% | 76.63M▲ 0% |
Free Cash Flow | -14.26M▲ 0% | -14.18M▲ 0.6% | -6.82M▲ 51.9% | -10.6M▼ 55.4% | -18.01M▼ 69.8% | 1.56M▲ 108.6% | -27.64M▼ 1875.6% | -41.53M▼ 50.2% | -72.72B▼ 174972.1% | -113.96M▲ 0% |
FCF Margin % | -535% | -848.53% | -678.74% | -3417.38% | -7352.29% | 61.02% | -109.79% | -186.5% | - | - |
FCF Growth % | 10.83% | 0.59% | 51.89% | -55.43% | -69.83% | 108.65% | -1875.58% | -50.25% | -174972.15% | -141.57% |
FCF per Share | -5.32 | -4.82 | -1.84 | -0.68 | -0.78 | 0.06 | -1.03 | -1.18 | -1564.51 | -1.98 |
FCF Conversion (FCF/Net Income) | -5.85x | 0.91x | 0.89x | 0.74x | 0.84x | -0.17x | 1.15x | 0.99x | 664.59x | 0.99x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CAPR Key Ratios
Capricor Therapeutics, Inc. (CAPR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 67.31% | -191.78% | -133.42% | -77.95% | -67.23% | -134.49% | -129.63% | -48.16% | -46.56% | -59.27% |
Return on Invested Capital (ROIC) | -163.71% | -422.38% | -351.93% | - | - | -1087.55% | -242.63% | -43.8% | -92.95% | -91.09% |
Gross Margin | 100% | 100% | -411.61% | 100% | 100% | -755.07% | -44.76% | -124.37% | - | - |
Net Margin | 91.19% | -909.1% | -760.36% | -4401.94% | -8175.86% | -1137.37% | -88.52% | -181.71% | - | - |
Debt / Equity | - | - | - | 0.01x | 0.09x | 0.22x | 0.10x | 0.01x | 0.07x | 0.08x |
Interest Coverage | 7.10x | - | - | - | - | - | - | - | -35.51x | -38.82x |
FCF Conversion | -5.85x | 0.91x | 0.89x | 0.74x | 0.84x | -0.17x | 1.15x | 0.99x | 664.59x | 0.99x |
Revenue Growth | -16.43% | -37.32% | -39.85% | -69.13% | -21.06% | 941.85% | 886.81% | -11.55% | -100% | -100% |
Related:CAPR Dividend History·CAPR Revenue History·CAPR Price History·CAPR P/E History·CAPR Financial Ratios·CAPR Institutional Holders
CAPR SEC Filings & Documents
Capricor Therapeutics, Inc. (CAPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
CAPR Frequently Asked Questions
Capricor Therapeutics, Inc. (CAPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Capricor Therapeutics, Inc. (CAPR) saw revenue decline by 100.0% over the past year.
Capricor Therapeutics, Inc. (CAPR) reported a net loss of $114.6M for fiscal year 2025.
Dividend & Returns
Capricor Therapeutics, Inc. (CAPR) has a return on equity (ROE) of -46.6%. Negative ROE indicates the company is unprofitable.
Capricor Therapeutics, Inc. (CAPR) had negative free cash flow of $114.0M in fiscal year 2025, likely due to heavy capital investments.